Bipolar Disorder: Clinical Trials

15 trials for Bipolar Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 recruiting. 15 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 215Recruiting 15
Phase 12Recruiting 2
Phase 31Recruiting 1

Follow Bipolar Disorder: new trials by email Literature Review of Bipolar Disorder trials Research Report on Bipolar Disorder

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)
Ketamine Hydrochloride, Midazolam Hydrochloride, Dialectical Behavioral Therapy (DBT) - Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder
Phase 2RecruitingJoshua Rosenblat1202026-07-162026-07-29
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder
psilocybin (25 mg), psilocybin 1mg micro-dose - Bipolar II Depression
Phase 2RecruitingLakshmi N Yatham902026-06-152026-09-15
Melatonin Versus Placebo for Bipolar Disorder
Melatonin, Placebo - Bipolar Affective Disorder
Phase 2RecruitingLars Vedel Kessing2002026-05-082026-05-12
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
Icalcaprant, Placebo for Icalcaprant - Bipolar I Disorder, Bipolar II Disorder
Phase 2RecruitingAbbVie1952026-02-032026-08-14
The PEDAL Intervention - Reducing Affective Lability in Bipolar Disorder
Traditional group psychoeducation for bipolar disorder, Group psychoeducation with digital elements and focus on affective lability - Bipolar Disorder (BD)
Phase 2RecruitingOslo University Hospital1202025-12-012026-09-04
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Brenipatide, Placebo - Bipolar Disorder
Phase 2RecruitingEli Lilly and Company4002025-11-242026-10-07
Adaptation and Validation of the Hypomanic Personality Scale (HPS-6) to Romanian
Hypomanic Personality Scale - 6 - Bipolar Disorder (BD)
Phase 1 / Phase 2RecruitingBabes-Bolyai University502025-09-222026-02-10
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
Psilocybin, Therapeutic Support - Bipolar II Disorder, Depression, Bipolar
Phase 2RecruitingThe University of Texas Health Science Center, Houston102025-07-072026-08-12
Correcting Circadian Rhythms to Breakthrough in Bipolar Disorder
Melatonin, Placebo, Behavioral sleep intervention - Bipolar Disorder, Delayed Sleep-Wake Phase Disorder
Phase 2RecruitingLeslie Swanson502024-08-132026-05-11
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Sigma-Stim, RUL LAP-ST (Low-Amplitude Pulse Seizure Therapy - Right Unilateral) - Suicidal Ideation, Major Depressive Disorder
Phase 2 / Phase 3RecruitingMichigan State University302024-07-032026-08-12
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
Exercise Session, Ibuprofen 800 mg, Rest - Bipolar Depression
Phase 1 / Phase 2RecruitingLaureate Institute for Brain Research, Inc.202024-03-122025-05-23
NMDA Receptor Modulation for the Treatment of Bipolar I Disorder
NMDAE, Placebo Cap - Bipolar I Disorder
Phase 2RecruitingChina Medical University Hospital902023-10-042026-10-23
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
Cannabidiol - Bipolar Disorder
Phase 2RecruitingMclean Hospital252023-06-012026-03-30
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
Perampanel 6 MG, Ketamine, Placebo - Depressive Disorder, Major Depressive Disorder
Phase 2RecruitingYale University302023-04-032026-05-06
OSU6162 in Bipolar Depression (OBID)
OSU6162 - Bipolar Depression
Phase 2RecruitingGöteborg University222021-10-252026-09-15

Narrower conditions

Suicidal Ideation (4)  ·  Depressive Disorder, Major (3)  ·  Depression (2)  ·  Mood Disorders (2)  ·  Suicide (2)  ·  Bipolar and Related Disorders (1)  ·  Borderline Personality Disorder (1)  ·  Cyclothymic Disorder (1)  ·  Depressive Disorder (1)  ·  Depressive Disorder, Treatment-Resistant (1)  ·  Emotional Regulation (1)  ·  Mental Disorders (1)  ·  Psychotic Disorders (1)  ·  Sleep Disorders, Circadian Rhythm (1)

Broader conditions

Bipolar and Related Disorders (14)  ·  Mental Disorders (14)  ·  Mood Disorders (13)  ·  Behavior (6)  ·  Behavioral Symptoms (5)  ·  Self-Injurious Behavior (4)  ·  Depressive Disorder (2)  ·  Suicide (2)  ·  Chronobiology Disorders (1)  ·  Dyssomnias (1)  ·  Nervous System Diseases (1)  ·  Occupational Diseases (1)  ·  Personality Disorders (1)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (1)  ·  Self-Control (1)

Interventions

Ketamine (2)  ·  Melatonin (2)  ·  Psilocybin (2)  ·  Cannabidiol (1)  ·  Ibuprofen (1)  ·  MD1 (1)  ·  Midazolam (1)  ·  OSU 6162 (1)  ·  RE1-silencing transcription factor (1)  ·  Self-Help Groups (1)  ·  perampanel (1)

Sponsors

AbbVie (1)  ·  Babes-Bolyai University (1)  ·  China Medical University Hospital (1)  ·  Eli Lilly and Company (1)  ·  Göteborg University (1)  ·  Joshua Rosenblat (1)  ·  Lakshmi N Yatham (1)  ·  Lars Vedel Kessing (1)  ·  Laureate Institute for Brain Research, Inc. (1)  ·  Leslie Swanson (1)  ·  Mclean Hospital (1)  ·  Michigan State University (1)  ·  Oslo University Hospital (1)  ·  The University of Texas Health Science Center, Houston (1)  ·  Yale University (1)

Countries

United States (8)  ·  Canada (2)  ·  Argentina (1)  ·  Brazil (1)  ·  China (1)  ·  Denmark (1)  ·  India (1)  ·  Japan (1)  ·  Mexico (1)  ·  Norway (1)  ·  Puerto Rico (1)  ·  Romania (1)  ·  Sweden (1)  ·  Taiwan (1)

Top investigators

Dr. Lakshmi N Yatham (1)  ·  Joshua D. Rosenblat, MD, MSc (1)  ·  Lars Kessing (1)  ·  Leslie Swanson, PhD (1)  ·  Nagy A Youssef, MD, PhD (1)  ·  Naomi Driesen, PhD (1)  ·  Thomas Meyer, PhD (1)

Results publications

PMID 42442821

NIH funding

R21MH132901 (1)